Next Article in Journal
Factors Influencing the Outcome of Stereotactic Radiosurgery in Patients With Five or More Brain Metastases
Previous Article in Journal
Effects of Magnanimous Therapy on Coping, Adjustment, and Living Function in Advanced Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4167
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy

by
Maryam Dosani
1,*,
R. Yang
1,
M. McLay
2,
D. Wilson
3,
M. Liu
1,
C. J. Yong-Hing
4,
J. Hamm
5,
C. R. Lund
6,
R. Olson
2 and
D. Schellenberg
6
1
Department of Radiation Oncology and Developmental Therapeutics, BC Cancer–Vancouver Centre, and Department of Surgery, Faculty of Medicine, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada
2
Department of Radiation Oncology and Developmental Therapeutics, BC Cancer–Centre for the North, and Department of Surgery, Faculty of Medicine, Prince George, BC, Canada
3
Department of Functional Imaging, BC Cancer–Vancouver Centre, Vancouver, BC, Canada
4
Department of Radiology, BC Cancer–Vancouver Centre, and Department of Radiology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
5
Cancer Surveillance and Outcomes, BC Cancer, Vancouver, BC, Canada
6
Department of Radiation Oncology and Developmental Therapeutics, BC Cancer–Fraser Valley Centre, Surrey, and Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 57-63; https://doi.org/10.3747/co.26.4167
Submission received: 4 November 2018 / Revised: 6 December 2018 / Accepted: 12 January 2019 / Published: 1 February 2019

Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (NSCLC). Previous studies have demonstrated a prognostic value for positron emission tomography–computed tomography (PET/CT) parameters, including maximal standardized uptake value (SUVmax), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (LC) and overall survival (OS) in patients treated with SABR for NSCLC. Methods: We conducted a retrospective review of patients treated with SABR for stage i inoperable NSCLC at BC Cancer between 2009 and 2013. The Akaike information criterion was used to compare the prognostic value of the various PET/CT parameters. Results: The study included 134 patients with a median age of 76 years. Median tumour diameter was 2.2 cm, gross tumour volume was 8.1 mL, SUVmax was 7.9, MTV was 2.4 mL, and tlg was 10.9 SUV•mL. The 2-year LC was 92%, and os was 66%. On univariate and multivariate analysis, imaging variables including tumour size, gross tumour volume, SUVmax, MTV, and tlg were all associated with worse LC. Tumour size was not associated with significantly worse OS, but other imaging variables were. The PET/CT parameter most prognostic of LC was MTV. Compared with SUVmax, TLG and MTV were more prognostic of OS. Conclusions: In patients with early-stage NSCLC treated with SABR, MTV appears to be prognostic of LC and OS.
Keywords: metabolic tumour volume; positron-emission tomography-computed tomography; PET/CT; non-smallcell lung cancer; NSCLC; stereotactic ablative radiotherapy; SABR; prognosis metabolic tumour volume; positron-emission tomography-computed tomography; PET/CT; non-smallcell lung cancer; NSCLC; stereotactic ablative radiotherapy; SABR; prognosis

Share and Cite

MDPI and ACS Style

Dosani, M.; Yang, R.; McLay, M.; Wilson, D.; Liu, M.; Yong-Hing, C.J.; Hamm, J.; Lund, C.R.; Olson, R.; Schellenberg, D. Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy. Curr. Oncol. 2019, 26, 57-63. https://doi.org/10.3747/co.26.4167

AMA Style

Dosani M, Yang R, McLay M, Wilson D, Liu M, Yong-Hing CJ, Hamm J, Lund CR, Olson R, Schellenberg D. Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy. Current Oncology. 2019; 26(1):57-63. https://doi.org/10.3747/co.26.4167

Chicago/Turabian Style

Dosani, Maryam, R. Yang, M. McLay, D. Wilson, M. Liu, C. J. Yong-Hing, J. Hamm, C. R. Lund, R. Olson, and D. Schellenberg. 2019. "Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy" Current Oncology 26, no. 1: 57-63. https://doi.org/10.3747/co.26.4167

APA Style

Dosani, M., Yang, R., McLay, M., Wilson, D., Liu, M., Yong-Hing, C. J., Hamm, J., Lund, C. R., Olson, R., & Schellenberg, D. (2019). Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy. Current Oncology, 26(1), 57-63. https://doi.org/10.3747/co.26.4167

Article Metrics

Back to TopTop